Does Rallies show 13F holders for GILD?

Yes. Rallies tracks hedge fund and 13F ownership data for GILD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GILD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.

GILD (Gilead Sciences) Stock Analysis - Hedge Fund Holdings

Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of May 20, 2026, GILD trades at $130.37 with a market cap of $160.99B and a P/E ratio of 17.61. GILD moved +0.10% today. Year to date, GILD is +7.32%; over the trailing twelve months it is +22.93%. Its 52-week range spans $81.83 to $157.29. Analyst consensus is strong buy with an average price target of $159.83. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GILD stock?

Hedge funds tracked by Rallies that own GILD include Panagora Asset, Pinebridge Investments, Bridgewater Associates, Orbimed Advisors, and Bluecrest Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Gilead Sciences.

GILD Key Metrics

Key financial metrics for GILD
Metric	Value
Price	$130.37
Market Cap	$160.99B
P/E Ratio	17.61
EPS	$7.42
Dividend Yield	0.82%
52-Week High	$157.29
52-Week Low	$81.83
Volume	3.70M
Avg Volume	0
Revenue (TTM)	$29.74B
Net Income	$9.22B
Gross Margin	79.36%

Top Hedge Funds Holding GILD

Panagora Asset holds 1.17M shares of GILD, changed -6.44% as of Mar 31, 2026.
Pinebridge Investments holds 180.84K shares of GILD, changed -12.95% as of Sep 30, 2025.
Bridgewater Associates holds 180.74K shares of GILD, changed -38.19% as of Mar 31, 2026.
Orbimed Advisors holds 59.60K shares of GILD, changed -69.82% as of Mar 31, 2026.
Bluecrest Capital holds 13.55K shares of GILD, changed +0.00% as of Jun 30, 2025.

Latest GILD News

Gilead Sciences Prices $3 Billion Notes at 4.25%-4.90% Across Four Maturities — May 15, 2026
Gilead Tops Q1 Estimates with 12% HIV, 28% Trodelvy Sales Growth — May 8, 2026
Gilead Cuts Full-Year Guidance, Expects Loss on Acquired R&D Charges — May 7, 2026
California High Court Weighs Gilead’s Liability to 24,000 HIV Patients Over TAF — May 6, 2026
Gilead to Expand ADC Pipeline with $5 Billion Tubulis Deal, Shares Up 1.97% — Apr 8, 2026

Recent GILD Insider Trades

Dickinson Andrew D sold 3.00K (~$396.81K) on May 15, 2026.
Mercier Johanna sold 7.75K (~$1.01M) on May 15, 2026.
Mercier Johanna sold 11.18K (~$1.47M) on May 15, 2026.

GILD Analyst Consensus

22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.83.

Common questions about GILD

Who owns GILD stock?: Hedge funds tracked by Rallies that own GILD include Panagora Asset, Pinebridge Investments, Bridgewater Associates, Orbimed Advisors, and Bluecrest Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Gilead Sciences.
Does Rallies show 13F holders for GILD?: Yes. Rallies tracks hedge fund and 13F ownership data for GILD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GILD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.